Novo Nordisk ASHAM:NOVA -0.48%81 Current Ratio is 0.79 as of Mar. 2026, which is 17% below its 10-year median of 0.95. GuruFocus rates HAM:NOVA with a GF Score™ of 81/100 and a GF Value™ of €119.15 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 995 Drug Manufacturers companies, Novo Nordisk AS ranks worse than 89.05% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Novo Nordisk AS's current ratio for the quarter that ended in Mar. 2026 was 0.79.
Novo Nordisk AS has a current ratio of 0.79. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Novo Nordisk AS has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Novo Nordisk AS's Current Ratio or its related term are showing as below:
HAM:NOVA'
s Current Ratio Range Over the Past 10 Years
Min: 0.7 Med: 0.95 Max: 1.35
Current: 0.79
During the past 13 years, Novo Nordisk AS's highest Current Ratio was 1.35. The lowest was 0.70. And the median was 0.95.
HAM:NOVA's Current Ratio is ranked worse than 89.05% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs HAM:NOVA: 0.79
Novo Nordisk AS (HAM:NOVA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Novo Nordisk AS Current Ratio Related Terms
Novo Nordisk AS Current Ratio Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:NOVA vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Current Ratio distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (HAM:NOVA) has a Current Ratio of 0.79 as of Mar. 2026. This is 17% below median its historical median of 0.95. Over the past decade, Novo Nordisk AS's Current Ratio has ranged from 0.70 to 1.35. According to the industry distribution chart, Novo Nordisk AS ranks #886 out of 995 companies in the Drug Manufacturers industry, placing it in the top 89%.
Is Novo Nordisk AS's Current Ratio too high?
Novo Nordisk AS's current Current Ratio of 0.79 is 17% below median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 1.35. The Drug Manufacturers industry median Current Ratio is 2.00. Novo Nordisk AS's value of 0.79 is 60.5% below this industry median. Based on the distribution chart, Novo Nordisk AS ranks #886 out of 995 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #886 out of 995 companies for Current Ratio. This places Novo Nordisk AS in the lower half of its industry. The industry median Current Ratio is 2.00. Novo Nordisk AS's value of 0.79 is 60.5% below this benchmark. Historically, Novo Nordisk AS's own Current Ratio has ranged from 0.70 to 1.35 over the past decade. While the company's 10-year median is 0.95 vs. the industry median of 2.00, Novo Nordisk AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Current Ratio of 0.79 is 60.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Current Ratio is 0.79, which is 17% below median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (HAM:NOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is €119.15, compared to a current price of €41.80 — trading 64.9% below its estimated fair value. The current Current Ratio is 0.79, which is 17% below median its 10-year median of 0.95 and 60.5% below the Drug Manufacturers industry median of 2.00. Novo Nordisk AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Novo Nordisk AS (HAM:NOVA), the current Current Ratio is 0.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €41.80 is trading 64.9% below its estimated GF Value™ of €119.15.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for HAM:NOVA:
Current Ratio: 0.79 (17% below median its 10-year median of 0.95)
GF Value™: €119.15 vs. price of €41.80 (64.9% below fair value)
Industry Position: 60.5% below the Drug Manufacturers median (#886 of 995)
No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
81GF Score
Get the complete analysis for HAM:NOVA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:NOVA has been successfully added to your 
